Glafenine


Generic Medicine Info
Indications and Dosage
Oral
Pain and inflammation
Adult: 200-400 mg 3-4 times daily.
Child: 10-15 yr: 200 mg tid; 5-9 yr: 100 mg tid.
Contraindications
Peptic ulceration; hypersensitivity to NSAIDs/aspirin; moderate/severe renal impairment.
Special Precautions
Liver failure. Drink plenty of fluid to reduce the risk of crystallization in the urinary tract. To be discontinued at the 1st sign of allergic reaction. Patient with infection; haemorrhagic disorders; hypertension; cardiac function; asthma. Pregnancy and lactation.
Adverse Reactions
Anaphylaxis; hepatotoxicity; nephrotoxicity; GI disturbances; crystallization in the urinary tract; cross-reactivity with floctafenine.
Drug Interactions
Oral anticoagulants; antivirals; phenytoin; sulfonylurea antidiabetic; methotrexate; cardiac glycosides; ACE inhibitors; diuretics; β-blocker; other NSAIDs; lithium; ciclosporin; tacrolimus; moclobemide. Corticosteroids; antiplatelet drugs, biphosphonates, SSRIs and pentoxifylline increase GI bleeding risk. Avoid alcohol and tobacco.
Potentially Fatal: Quinolones: Convulsion may occur.
Lab Interference
Thyroid function tests: Lowers serum thyroid hormone levels.
Action
Description:
Mechanism of Action: Glafenine is an NSAID, from the anthranilic acid derivative. Its high incidence of anaphylactic reactions led to its withdrawal from the market in most countries.
MIMS Class
Analgesics (Non-Opioid) & Antipyretics
Disclaimer: This information is independently developed by MIMS based on Glafenine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in